Frontlight ResearchEarly access
WithdrawnNo phase
Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension
Key facts
- Who runs it
- The Second Affiliated Hospital of Chongqing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Mar 2025
- Ended
- Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Renal sympathetic denervation
- Renal sympathetic denervation plus aorticorenal ganglion ablation
- Record updated
- 14 May 2025
- Why it stopped
- The hospital ethics review for this study is currently underway, and participant recruitment will commence once the approval is granted.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Male and non-pregnant female subjects
- 18≤age≤70 years old
- Primary hypertension
- 24-hour ASBP ≥130mmHg after standard anti-hypertensive drug therapy
- Arteries meet the criteria of catheter manipulation
- Patient understands the purpose of this study, and is willing to participate and sign the informed consent
- Patient is compliant and willing to complete clinical follow-up
Who cannot take part
- Participated other clinical trials including both drug and medical device studies within 3 months enrollment
- Patients previously or currently suffering from one of the following diseases: 1) Essential pulmonary arterial hypertension; 2) Type I diabetes; 3) Severe cardiac valvular stenosis; 4) History of myocardial infraction (MI), unstable angina, syncope or cerebrovascular accidents within half year; 5) History of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyroidism; 6) Any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia); 7) Plans to have surgery or cardiovascular interventions within following 6 months; 8) Alcohol abuse or unknown drug dependence history; 9) Neuroticisms such as depression or anxiety disorders; 10) Non-compliant patients unable to finish the research per physician's requests
- Abdominal aorta and renal arteries are not eligibility for catheter manipulation: 1) Renal artery stenosis >50% or any renal artery aneurysms on either side 2) History of renal artery percutaneous transluminal angioplasty (PTA), including balloon angioplasty and stenting; 3) abdominal aortic dissection, ulceration, or stenosis
- eGFR <45ml/min/1.73m2 (MDRD formula)
- Hospitalized within one year due to hypertensive crisis
- Female with pregnant or lactating, or having plans for pregnancy within 1 year
- Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this prospective cohort proof-of-concept trial is to compare the efficacy and safety of renal sympathetic denervation (RSD) plus aorticorenal ganglion ablation versus RSD alone in the treatment of uncontrolled primary hypertension.
The 2 groups in the trial
- RSD groupExisting treatment, for comparison
High-frequency stimulation (HFS) guided radiofrequency ablation from accessible branches to the opening of the renal artery.
Treatment: Renal sympathetic denervation
- RSD+ARGA groupTreatment being tested
High-frequency stimulation (HFS) guided radiofrequency ablation from accessible branches to the opening of the renal artery, as well as HFS-guided ARG ablation.
Treatment: Renal sympathetic denervation plus aorticorenal ganglion ablation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety Comparison of Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation vs. Renal Sympathetic Denervation Alone for the Treatment of Hypertension: A Multicenter, Prospective, Proof-of-concept Cohort Trials.
- Record updated
- 14 May 2025